Trimmune Biotech

Trimmune Biotech is a biotechnology company specializing in the development of next-generation multi-specific antibody therapies for cancer immunotherapy. The company's core technology is the Tri-specific T-cell Engager (TriTE) platform, which simultaneously targets CD3 and CD28 on T-cells along with a tumor-associated antigen to enhance T-cell activation and persistence. Their pipeline includes candidates targeting BCMA for multiple myeloma and HER2 for solid tumors, aiming to overcome the limitations of current bispecific antibodies. Trimmune's approach focuses on providing a more potent and durable immune response while maintaining a favorable safety profile. The company operates with research and development facilities in both China and the United States.